Weekly topotecan for recurrent endometrial cancer: A case series and review of the literature Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Endometrial Neoplasms
  • Neoplasm Recurrence, Local
  • Topotecan

abstract

  • Weekly topotecan has antitumor activity and is well tolerated in patients with recurrent endometrial cancer, including those patients with multiple prior treatments. Topotecan on a weekly bolus schedule should be evaluated in prospective trials to better establish its role in the treatment of recurrent endometrial cancer.

publication date

  • October 2004

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2004.07.035

PubMed ID

  • 15385138

Additional Document Info

start page

  • 235

end page

  • 41

volume

  • 95

number

  • 1